Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

UGN-102 Elicits Durable Responses in Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

November 17th 2020

November 17, 2020 - Primary chemoablation with UGN-102 was found to induce durable responses in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer.

Novel Mechanism of Action and Tolerability Makes Telaglenastat a Promising Player in RCC

November 17th 2020

Chung-Han Lee, MD, PhD, discusses the promise of telaglenastat in renal cell carcinoma and the research efforts examining the agent in different combinations.

Cabozantinib Plus Nivolumab/Ipilimumab Under Exploration in Intermediate-, Poor-Risk RCC

November 14th 2020

November 14, 2020 - A novel combination comprised of the TKI cabozantinib plus the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab is under exploration in treatment-naïve patients with intermediate or poor risk advanced or metastatic renal cell carcinoma in the phase 3 COSMIC-313 trial.

Dr. George on the Specificity of Cabozantinib in RCC

November 13th 2020

Daniel J. George, MD, discusses the expanding role of cabozantinib in renal cell carcinoma.

Dr. Lee on the Rationale for Evaluating Telaglenastat in RCC

November 13th 2020

Chung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.

Dr. Campbell on the Expanding Role of Cabozantinib in RCC

November 12th 2020

Matthew T. Campbell, MD, MS, discusses the expanding role of cabozantinib in renal cell carcinoma.

Dr. Hutson on Remaining Questions With the Durability of Immune Responses in RCC

November 12th 2020

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

Dr. Zhang on the Combination of LAG525 and Spartalizumab in Advanced Malignancies

November 12th 2020

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma Landscape

November 12th 2020

Monoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.

First Nonoperative Option Arrives for Low-Grade UTUC

November 11th 2020

Seth P. Lerner, MD, FACS, discusses the complexities of treating LG-UTUC and how mitomycin gel for instillation addresses an unmet need in this space.

Frontline Pembrolizumab/Lenvatinib Significantly Improves Survival, Responses in Advanced RCC

November 10th 2020

November 10, 2020 - The combination of pembrolizumab plus lenvatinib significantly improved progression-free survival, overall survival, and the objective response rate compared with sunitinib, when used in the frontline treatment of patients with advanced renal cell carcinoma.

Surgical Delays Caused By COVID-19 Do Not Increase Risk of pT3a Upstaging, Compromise OS in cT1b-cT2b RCC

November 9th 2020

The coronavirus disease 2019 pandemic has led to delays in elective and potentially curative surgeries for patients with cT1b-cT2b renal cell carcinoma but research has indicated that surgical delays of up to and beyond 3 months did not result in an increased risk of pT3a upstaging or comprise overall survival.

Clinical Activity, Safety of Modified Nivolumab/Ipilimumab Dose in RCC Confirm Best Practices

November 7th 2020

A modified dosing schedule of frontline nivolumab (Opdivo) and ipilimumab (Yervoy) compared with the standard dose showed no differences in responses or safety in patients with advanced renal cell carcinoma, according to results of the CheckMate-920 trial.

Low-Dose Lenvatinib Shows Similar Safety to Standard Dose in RCC, But Noninferiority Cannot Be Claimed

November 7th 2020

A 14-mg dose of lenvatinib showed similar safety to the standard 18-mg dose of the agent, when used in combination with everolimus in the second-line treatment of patients with advanced renal cell carcinoma, but noninferiority could not be confirmed.

Future of VHL Disease–Associated RCC Bright, With Immunotherapy and HIF-2α, CDK4/6 Inhibitors Part of Ongoing Research

November 7th 2020

Recent research for effective therapies designed to target von Hippel-Lindau disease–associated renal cell carcinoma is pointing to a future with the paradigm that comprises immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors.

Choosing Among First-Line IO/TKI Combos in RCC: The Affordable Option Is the Winner

November 7th 2020

Combination regimens comprised of immunotherapy and TKI inhibitors have yielded significant benefits in terms of overall survival and progression-free survival with acceptable safety in patients with renal cell carcinoma; however, the cost of these regimens may negate the impact of these advances.

Dr. McGregor the Potential Utility of Cabozantinib/Nivolumab in Advanced RCC

November 7th 2020

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Dr. Choueiri on the Rationale for the COSMIC-313 Trial in Advanced RCC

November 7th 2020

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

Lenvatinib/Pembrolizumab Shows Promise After PD-1/PD-L1 Inhibition in Metastatic Clear Cell RCC

November 6th 2020

The combination of lenvatinib plus pembrolizumab demonstrated encouraging antitumor activity in patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy.

Dr. Rini on Choosing Between IO/IO or IO/TKI Combinations in mRCC

November 6th 2020

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.